Viking Therapeutics and Kymera report third-quarter 2026 losses with no revenue
According to TradingView, Viking Therapeutics posted zero revenue and a $183.2M loss in Q3 2026, while Kymera reported a $132M net loss.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Viking Therapeutics recorded no revenue in the third quarter of 2026, and its net loss reached $183.2 million, up from $90.8 million a year earlier. Diluted loss per share rose to $(1.55) from $(0.81). The company said its Phase 3 VANQUISH-1 and VANQUISH-2 trials of injectable VK2735 for obesity completed enrollment, and the oral VK2735 SUNRISE program began in October 2026.
Kymera Therapeutics also reported zero revenue for the quarter, compared with $2.8 million a year earlier. Its net loss grew to $132 million from $82.2 million, and loss per share was $(1.32) versus $(0.94). Nine-month collaboration revenue increased to $99.4 million from $36.3 million. The details come from TradingView, which based its summaries on documents filed with the SEC.
why it matters
For the market, this is routine reporting from small biotech companies that have no product sales yet. Clinical program progress and rising research spending remain the main drivers, and investors will focus mainly on upcoming trial data and partnership deals.
tags
instruments
sources
- Viking Therapeutics 3Q 2026: Revenue $0 Net loss $183.2M, EPS $(1.55) — 10-Q Summary — TradingView, 29 October 2026 at 10:01 UTC
- Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary — TradingView, 29 October 2026 at 11:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗